Construction method of yarrowia lipolytica engineering strain with melatonin biosynthesis function and yarrowia lipolytica engineering strain

By constructing Yarrowia lipolytic strains, the biosynthesis of melatonin was achieved, which solved the lack of adaptability and efficiency of E. coli and Saccharomyces cerevisiae, and improved the yield and synthesis efficiency of melatonin, which was suitable as a safe Industrial production host.

CN119081904APending Publication Date: 2024-12-06GUANGDONG TECHNION ISRAEL INST OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411283405.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Among the existing melatonin production methods, E. coli is not suitable for high pH or high temperature environments and may produce toxins. The metabolic system of Saccharomyces cerevisiae is not strong enough, resulting in low efficiency and complexity of melatonin synthesis, which limits the difficulty of optimization of production.

Method used

Yarrowia lipolytic strains with highly efficient and stable expression of tryptophan hydroxylase, tryptophan decarboxylase, serotonin n-acetyltransferase and n-acetyl5-hydroxyserotonin methyltransferase were constructed, through codons Optimization and gene synthesis have achieved the biosynthesis of melatonin.

Benefits of technology

It improves the yield and synthesis efficiency of melatonin, simplifies the production process, is suitable as a safe industrial production host, and is adapted to a variety of culture conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119081904A_ABST
    Figure CN119081904A_ABST
Patent Text Reader

Abstract

The invention provides a construction method of a yarrowia lipolytica engineering strain with a melatonin biosynthesis function and the yarrowia lipolytica engineering strain, and relates to the technical field of gene engineering. The yarrowia lipolytica engineering strain can efficiently and stably express tryptophan hydroxylase, tryptophan decarboxylase, 5-hydroxytryptamine n-acetyltransferase and n-acetyl 5-hydroxytryptamine methyltransferase, so that the biosynthesis of the melatonin is realized in the yarrowia lipolytica. In particular, the invention provides a gene AlTPH for coding tryptophan hydroxylase after codon optimization and a gene NfTPH for coding tryptophan hydroxylase after codon optimization. According to the AlTPH and NfTPH genes, the catalytic activity of hydroxylating L-tryptophan into 5-hydroxytryptophan can be effectively improved, and 5-HTP is increased, so that the yield of melatonin in the yarrowia lipolytica engineering strain is increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of genetic engineering, and in particular to a construction method of a Yarrowia lipolytica engineering strain having the function of biosynthesizing melatonin and the Yarrowia lipolytica engineering strain. Background Art

[0002] Melatonin is an important indoleamine with antioxidant and anti-inflammatory properties. It can also regulate a person's sleep and help relieve stress. Currently, the global demand for melatonin is increasing. In China, more and more people are troubled by sleep problems, which can be alleviated by taking melatonin.

[0003] Compared with traditional extraction from natural melatonin-producing species or chemical synthesis, the use of engineered microbial factories has gradually become an environmentally friendly, low-cost and potential way to produce industrial melatonin. Exploring potential microbial hosts, optimizing melatonin synthesis pathways, and achieving high melatonin production are issues that need to be considered and addressed. So far, melatonin production has been achieved in engineered Escherichia coli or Saccharomyces cerevisiae. However, E. coli is not suitable for certain culture conditions, such as high pH or temperature. In addition, some E. coli strains are toxin-producing strains that can cause foodborne diseases. The use of E. coli as a melatonin production host requires subsequent complex extraction and purification processes. The metabolic system in Saccharomyces cerevisiae for producing key substrates involved in melatonin synthesis is not as powerful as that in Yarrowia lipolytica.

[0004] The melatonin synthesis pathway constructed in Escherichia coli and Saccharomyces cerevisiae is the same as that in animals. In animals, the first catalytic reaction of 5-HTP synthesis requires cofactor tetrahydropterin (BH4) and oxygen, including the generation and regeneration pathway of BH4. In the first step of melatonin synthesis, another four or more heterologous genes need to be expressed, which is a difficult and complicated step. This will be greatly rate-limited, thus limiting the entire synthesis pathway to a certain extent. In addition, its complexity increases the difficulty of subsequent optimization of the pathway.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The object of the present invention is to provide a method for constructing a Yarrowia lipolytica engineered strain having the function of biosynthesizing melatonin and a Yarrowia lipolytica engineered strain, wherein the Yarrowia lipolytica engineered strain can efficiently and stably express tryptophan hydroxylase (TPH), tryptophan decarboxylase (TDC), 5-hydroxytryptamine n-acetyltransferase (SNAT) and n-acetyl 5-hydroxytryptamine methyltransferase (ASMT), thereby realizing the biosynthesis of melatonin in Yarrowia lipolytica.

[0007] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0008] In a first aspect of the present invention, the present invention provides an engineered strain of Yarrowia lipolytica, wherein the genome of the engineered strain of Yarrowia lipolytica comprises:

[0009] The codon-optimized gene encoding tryptophan hydroxylase, AlTPH;

[0010] and, the codon-optimized gene encoding tryptophan decarboxylase, CKvTDC;

[0011] and, the codon-optimized gene encoding serotonin n -acetyltransferase, SgSNAT;

[0012] and, the codon-optimized gene encoding n-acetyl 5-hydroxytryptamine methyltransferase HsASMT.

[0013] Figure 1 A schematic diagram of the melatonin biosynthesis pathway provided by the present invention.

[0014] Depend on Figure 1 It can be seen that the biosynthesis of melatonin starts from L-tryptophan and goes through four enzymatic reaction steps.

[0015] (1) L-tryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase (AlTPH).

[0016] (2) 5-HT is further decarboxylated by tryptophan decarboxylase (CKvTDC) to form serotonin.

[0017] (3) Serotonin n-acetyltransferase (SgSNAT) catalyzes the conversion of 5-hydroxytryptamine acetylase into n-acetyl 5-hydroxytryptamine (N-Acetylserotonin).

[0018] (4) n-acetyl 5-hydroxytryptamine is methylated and converted into melatonin by n-acetyl 5-hydroxytryptamine methyltransferase (HsASMT).

[0019] See also Figure 1 It can be seen that the synthesis of melatonin from L-tryptophan goes through four enzymatic reaction steps. The present application screened out four key enzymes of the melatonin biosynthesis pathway with high activity and stable expression from different organisms.

[0020] Specifically, four heterologous genes encoding the melatonin biosynthetic pathway (TPH of Actinomadura luzonensis, TDC of Candidatus Koribacter Ellin345, SNAT of Streptomyces griseofuscus, and ASMT of Homo sapiens) were codon-optimized with Y. lipolytica as the target, and then the genes were synthesized and cloned.

[0021] The codon-optimized nucleotide sequence encoding the tryptophan hydroxylase gene AlTPH is shown in SEQ ID NO.1;

[0022]

[0023] The codon-optimized nucleotide sequence encoding the tryptophan decarboxylase gene CKvTDC is shown in SEQ ID NO.2;

[0024]

[0025] The codon-optimized nucleotide sequence encoding the 5-hydroxytryptamine n-acetyltransferase gene SgSNAT is shown in SEQ ID NO.3;

[0026] The specific SEQ ID NO.3 sequence is as follows: ATGAACACTTTCCGTACAGCAACGGCACGAGACATTCCTG ACGTTGCAGCCACACTCACTGAGGCATTCGCCACTGATCCCCCACTCAATGGGTGTTTCCCGACGGTACGGCTGCAGTTTCGCGATTCTTCACGCATGTCGCAGATCGTGTCCATACCGCTGGCG GAATCGTGGAACTGCTCCCTGATCGTGCCGCAATGATCGCACTCCCCCCTCCATGTGCGTCTGCCTGGCGAGGCAGCTGACGGCAGACAGGCTGAGATCCAGAGACGGCTCGCTGATAGACATCCTCT GACGCCTCATTATTATCTCCTTTTTTATGGTGTGCGTACCGCACACCAGGGTTCCGGTCTGGGTGGACGGATGCTGGCTCGGCTTACCTCTAGAGCCGATAGAGACAGAGTCGGAACATATACAGAA GCAAGCACGTGGAGAGGAGCCAGACTGATGCTCAGACATGGATTCCACGCTACTCGGCCCCTCCGACTGCCCGACGGACCTAGCATGTTTCCCCTTTGGCGTGACCCTATTCACGACCACTCTGAT.

[0027] The codon-optimized nucleotide sequence encoding the n-acetyl 5-hydroxytryptamine methyltransferase gene HsASMT is shown in SEQ ID NO.4;

[0028] The specific sequence of SEQ ID NO.4 is as follows: ATGGGCAGCTCGGAAGACCAGGCTTATCGACTGCTTAACGACTACGCTAACGGATTTATGGTCTCTCAGGTGCTTTTTGCCGCTTGCGAGCTTGGAGTGTTCGACCTCCTTGCTGAGGCCCCTGGCCCTCTTGACGTCGCTGCTGTTGCTGCCGGTGTTCGAGCCTCCGCACACGGAACCGAGCTCCTCCTCGACATCTGCGTCAGCCTTAAGCTCCTTAAAGTTGAAACGCGAGGAGGAAAGGCTTTTTATCGAAACACCGAGCTGTCTTCGGACTATCTGACAACTGTTAGCCCTACTAGCCAATGTTCCATGCTCAAATACATGGGCAGAACGTCGTACCGTTGTTGGGGTCACCTGGCCGATGCAGTGCGAGAAGGACGGAACCAGTATCTTGAAACATTTGGAGTTCCTGCAGAGGAGCTTTTTACCGCAATTTATCGGTCTGAAGGAGAGAGACTCCAGTTTATGCAGGCCCTTCAAGAGGTCTGGTCCGTGAACGGACGATCCGTCCTGACAGCCTTTGACCTGTCGGTGTTCCCTCTGATGTGCGACCTCGGCGGCGGTGCCGGAGCTCTCGCAAAAGAATGCATGAGCCTGTATCCCGGTTGCAAAATTACAGTGTTTGATATTCCCGAAGTTGTTTGGACGGCCAAACAACACTTTTCCTTCCAGGAAGAAGAACAGATTGATTTCCAAGAGGGTGATTTTTTCAAAGATCCTCTTCCTGAAGCTGATCTCTATATTCTGGCCAGAGTTCTGCATGATTGGGCTGATGGTAAATGTTCCCATCTTCTCGAGCGGATCTACCATACATGCAAGCCTGGTGGTGGCATTCTCGTGATCGAATCCCTTCTCGATGAGGACCGTCGTGGTCCCCTGCTTACCCAACTGTACTCCCTGAATATGCTTGTGCAGACCGAAGGTCAAGAGCGGACACCCACCCATTATCATATGCTCCTTAGCTCTGCTGGCTTTCGGGACTTCCAGTTTAAGAAGACAGGCGCTATCTACGATGCTATCCTTGCACGGAAA。

[0029] The codon-optimized nucleotide sequence encoding the tryptophan hydroxylase gene NfTPH is shown in SEQ ID NO.5.

[0030]

[0031] This application starts with the four enzymatic reaction steps of synthesizing melatonin from L-tryptophan, screens out 4 key enzymes of the melatonin biosynthesis pathway with high activity and stable expression from different organisms, and performs codon optimization, and then synthesizes and clones the genes to obtain an engineered strain of Yarrowia lipolytica. The engineered strain of Yarrowia lipolytica can efficiently and stably express tryptophan hydroxylase (TPH), tryptophan decarboxylase (TDC), 5-hydroxytryptamine n-acetyltransferase (SNAT) and n-acetyl 5-hydroxytryptamine methyltransferase (ASMT), thereby realizing the biosynthesis of melatonin in Yarrowia lipolytica.

[0032] In particular, for the first enzymatic reaction step of "L-tryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH), the present application selected an alternative enzyme TPH in A. luzonensis, which only requires oxygen to participate in the catalytic reaction without additional cofactors. Furthermore, the present application has engineered the alternative enzyme TPH (including site-directed mutation and saturation mutation of the protein) to obtain a codon-optimized tryptophan hydroxylase gene AlTPH and a codon-optimized tryptophan hydroxylase gene NfTPH. The above-mentioned AlTPH and NfTPH genes can effectively improve the catalytic activity of hydroxylation, thereby improving enzyme activity and increasing the production of 5-HTP.

[0033] It should be noted that Yarrowia lipolytica is used as a production host for melatonin. Yarrowia lipolytica is a non-traditional yeast that is considered a "safe-for-use organism" and has been granted GRAS (generally recognized as safe) and can be used in industries such as food and pharmaceuticals. It has the advantages of strong robustness, high cell density, and low substrate cost, and is a high-potential host for metabolic engineering. At the same time, due to the physiological, metabolic, and genomic characteristics of Yarrowia lipolytica, Yarrowia lipolytica is also suitable as a platform for melatonin production. For example, a large amount of acetyl-CoA in lipolytic bacteria can provide a substrate for the third step of melatonin biosynthesis.

[0034] In a preferred embodiment of the present application, the engineered Yarrowia lipolytica strain is a Yarrowia lipolytica strain in which the endogenous genes ARO8 and MET25 are knocked out.

[0035] As a preferred embodiment, in order to increase the production of melatonin, the endogenous gene ARO8 of Yarrowia lipolytica in the present application is knocked out to block the flow of L-tryptophan to the indole-3-lactic acid (ILA) pathway. At the same time, the present application also uses the Yarrowia lipolytica strain with the MET25 gene knocked out as a chassis strain to increase the intracellular NADPH level, thereby enhancing TPH activity and increasing the production of 5-HTP.

[0036] In a second aspect of the present invention, the present invention provides a use of the above-mentioned Yarrowia lipolytica engineered strain in preparing a strain having the function of biosynthesizing melatonin.

[0037] In a fourth aspect of the present invention, the present invention provides a method for constructing an engineered strain of Yarrowia lipolytica having the function of biosynthesizing melatonin, the method comprising:

[0038] (A) The codon-optimized tryptophan hydroxylase gene AlTPH was obtained by gene synthesis technology;

[0039] and, the codon-optimized tryptophan decarboxylase gene CKvTDC;

[0040] and, the codon-optimized serotonin n -acetyltransferase gene SgSNAT;

[0041] and, the codon-optimized n -acetyl 5-hydroxytryptamine methyltransferase gene HsASMT;

[0042] (B) PCR amplification using the codon-optimized tryptophan hydroxylase gene AlTPH gene sequence as a template;

[0043] The gene sequence of the codon-optimized tryptophan decarboxylase gene CKvTDC was used as a template for PCR amplification;

[0044] The codon-optimized gene sequence of serotonin n-acetyltransferase gene SgSNAT was used as a template for PCR amplification;

[0045] The gene sequence of the codon-optimized n-acetyl 5-hydroxytryptamine methyltransferase gene HsASMT was used as a template for PCR amplification;

[0046] The primer sequences used for amplification in step (B) are as follows:

[0047]

[0048] (C) The AlTPH gene, CKvTDC gene, SgSNAT gene, and HsASMT gene amplified in step (B) were respectively connected into the pYLXP' linear vector that was double-digested with KpnI and SnaBI;

[0049] The pYLXP' expression vector containing AlTPH gene, the pYLXP' expression vector containing CKvTDC gene, the pYLXP' expression vector containing SgSNAT gene, and the pYLXP' expression vector containing HsASMT gene were constructed respectively;

[0050] (D) double-digesting the pYLXP' expression vector containing the AlTPH gene, the pYLXP' expression vector containing the CKvTDC gene, the pYLXP' expression vector containing the SgSNAT gene, and the pYLXP' expression vector containing the HsASMT gene obtained in step (C) with endonucleases to obtain an AlTPH gene expression cassette, a CKvTDC gene expression cassette, a SgSNAT gene expression cassette, and a HsASMT gene expression cassette with restriction ligation sites AvrII and SalI;

[0051] (E) The four gene expression cassettes obtained in step (D) are sequentially connected into the pUrlp plasmid vector that has been double-digested with NheI and SalI; the AvrII site is then single-digested with endonuclease to obtain a linear DNA carrying the target gene expression cassette;

[0052] (F) The linear DNA obtained in step (E) is transferred and integrated into the Yarrowia lipolytica genome, and the endogenous gene ARO8 is knocked out. After screening, an engineered strain of Yarrowia lipolytica having the function of biosynthesizing melatonin is obtained.

[0053] In a preferred embodiment of the present application, the step (F) is transferred to gene introduction mediated by lithium acetate-PEG.

[0054] In a preferred embodiment of the present application, the step (F) uses the URA3 gene as a screening marker to achieve the screening of yeast colonies containing the target introduced gene cassette. Compared with the prior art, the beneficial effects of the present invention are:

[0055] This application starts with the four enzymatic reaction steps of synthesizing melatonin from L-tryptophan, screens out 4 key enzymes of the melatonin biosynthesis pathway with high activity and stable expression from different organisms, and performs codon optimization, and then synthesizes and clones the genes to obtain an engineered strain of Yarrowia lipolytica. The engineered strain of Yarrowia lipolytica can efficiently and stably express tryptophan hydroxylase (TPH), tryptophan decarboxylase (TDC), 5-hydroxytryptamine n-acetyltransferase (SNAT) and n-acetyl 5-hydroxytryptamine methyltransferase (ASMT), thereby realizing the biosynthesis of melatonin in Yarrowia lipolytica.

[0056] In particular, for the first enzymatic reaction step of "L-tryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH), the present application screened an alternative enzyme TPH in A. luzonensis, which only requires oxygen to participate in the catalytic reaction without additional cofactors. Furthermore, the present application has engineered the alternative enzyme TPH (including site-directed mutation and saturation mutation of the protein) to obtain a codon-optimized tryptophan hydroxylase gene AlTPH and a codon-optimized tryptophan hydroxylase gene NfTPH. The above-mentioned AlTPH and NfTPH genes can effectively improve the catalytic activity of hydroxylation, thereby improving enzyme activity and increasing the production of 5-HTP. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0058] Figure 1 A schematic diagram of the melatonin biosynthesis pathway provided by the present invention;

[0059] Figure 2 A map of the pYLXP' plasmid vector provided in Example 1 of the present invention;

[0060] Figure 3 This is a map of the pUrlp plasmid vector provided in Example 1 of the present invention. DETAILED DESCRIPTION

[0061] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0062] The technical solution of the present invention will be further described below in conjunction with embodiments.

[0063] Sources of biological materials:

[0064] Chassis cells: Yarrowia lipolytica Po1g, Po1fk strains

[0065] Expression vector construction plasmids: pYLXP', pUrlp.

[0066] Example 1 Construction of expression vector

[0067] (I) Synthesis and amplification of target genes:

[0068] 1. Obtain the codon-optimized gene AlTPH encoding tryptophan hydroxylase using gene synthesis technology;

[0069] The codon-optimized gene CKvTDC encoding tryptophan decarboxylase;

[0070] The codon-optimized gene SgSNAT encoding serotonin n-acetyltransferase;

[0071] The codon-optimized gene HsASMT encoding n-acetyl 5-hydroxytryptamine methyltransferase;

[0072] 2. Using the above codon-optimized target gene sequence as a template, PCR amplification was performed to obtain DNA fragments of AlTPH, CKvTDC, SgSNAT, and HsASMT;

[0073] (II) Construction of recombinant expression plasmid

[0074] 1. Obtain pYLXP' and pUrlp plasmid vectors, both of which are from the Synthetic Biology and Intelligent Control Laboratory of Guangdong Technion-Israel Institute of Technology.

[0075] Figure 2 This is a map of the pYLXP' plasmid vector.

[0076] according to Figure 2 The pYLXP' vector is a circular plasmid containing a leucine Leu2 tag for screening in Yarrowia lipolytica. The vector also includes a strong promoter TEF and a terminator XPR2, which play an important role in the expression of the target gene in Yarrowia lipolytica. In addition, the upstream and downstream regions of the NotI restriction site contain about 1000 bp of pBR322 homology arms, allowing the integration of foreign genes into the pBR322 platform of the chassis strain.

[0077] Figure 3 This is a map of the pUrlp plasmid vector.

[0078] according to Figure 3 , pUrlp vector is also a circular plasmid containing leucine Leu2 and uracil Ura3 tags. The expression of uracil Ura3 gene is driven by TEF promoter and regulated by XPR2 terminator. In addition, LoxP sites are provided before TEF promoter and after XPR2 terminator, so that Ura3 screening marker gene can be recovered by Cre-LoxP system. pUrlp plasmid vector can also be inserted into the homologous arms upstream and downstream of the fixed integration site, so as to realize the fixed insertion and recombination of genes in chromosomes.

[0079] 2. The pYLXP' and pUrlp plasmid vectors were double-digested to obtain pYLXP' and pUrlp linearized vectors with sticky ends.

[0080] In this example, the pYLXP' plasmid vector was double-digested with KpnI (endonuclease 1) and SnaBI (endonuclease 2).

[0081] For the pUrlp plasmid vector, this example uses NheI (endonuclease 3) and SalI (endonuclease 4) for double restriction digestion.

[0082] The double enzyme digestion reaction system is shown in Table 1 (plasmid double enzyme digestion reaction system). The reaction conditions are 37° C. and the reaction time is 60 minutes.

[0083] Table 1: Plasmid double restriction enzyme digestion reaction system

[0084] Reagents Usage amount (μL) Plasmid vector 10 10X Buffer 2 Endonuclease 1 / 3 1 Endonuclease 2 / 4 1 Double distilled water 6

[0085] After the restriction digestion reaction was completed, the linearized pYLXP' vector fragment was separated by agarose gel electrophoresis, and the target fragment was recovered from the linearized pYLXP' vector fragment using a DNA gel recovery kit to obtain the purified plasmid linearized vector fragment.

[0086] 3. The linearized pYLXP' vector obtained in step 2 and the DNA fragments of the AlTPH, CKvTDC, SgSNAT, and HsASMT genes obtained in step 1 were assembled separately by seamless cloning technology (Gibson assembly) to construct pYLXP'-AlTPH, pYLXP'-CKvTDC, pYLXP'-SgSNAT, and pYLXP'-HsASMT (single gene) recombinant plasmids.

[0087] Table 2: Primers involved in plasmid construction:

[0088]

[0089] Table 3: PCR reaction program:

[0090]

[0091]

[0092] pYLXP'-AlTPH, pYLXP'-CKvTDC, pYLXP'-SgSNAT, pYLXP'-HsASMT (single gene) recombinant plasmids containing different target genes were digested by NheI (endonuclease 3) and SalI (endonuclease 4) and two combinations of AvrII (endonuclease 5) and SalI (endonuclease 4). Subsequently, the target single gene fragment was separated by agarose gel electrophoresis and DNA gel was used to recover the target single gene fragment. The recovered DNA fragment with the target gene was assembled by multi-gene subcloning (NheI and AvrII were the same enzyme-cut sticky ends) by T4 ligase, and finally constructed into pYLXP'-AlTPH-CKvTDC-SgSNAT-HsASMT (multi-gene) recombinant plasmid.

[0093] Table 4: T4 ligase reaction system:

[0094] Reagents Usage amount (μL) Vector gene fragment 2 Insert gene fragment 2 T4 Ligase 1 10X Buffer 1

[0095] 4. Assemble the target gene expression cassette in the pYLXP'-AlTPH-CKvTDC-SgSNAT-HsASMT (multi-gene) recombinant plasmid into the linearized pUrlp vector to obtain the pUrlp-AlTPH-CKvTDC-SgSNAT-HsASMT Yarrowia lipolytica chromosome site-directed recombinant plasmid.

[0096] The pYLXP'-AlTPH-CKvTDC-SgSNAT-HsASMT (multi-gene) recombinant plasmid was digested with AvrII (endonuclease 5) and SalI (endonuclease 4) to recover the target DNA fragment, and then connected and assembled with the linearized pUrlp vector obtained in step 2 by T4 ligase to obtain the pUrlp-AlTPH-CKvTDC-SgSNAT-HsASMT Yarrowia lipolytica chromosome site-directed recombinant plasmid.

[0097] Example 2

[0098] (I) Synthesis and amplification of target genes:

[0099] 1. Obtain the codon-optimized gene NfTPH encoding tryptophan hydroxylase using gene synthesis technology;

[0100] The codon-optimized gene CKvTDC encoding tryptophan decarboxylase;

[0101] The codon-optimized gene SgSNAT encoding serotonin n-acetyltransferase;

[0102] The codon-optimized gene HsASMT encoding n-acetyl 5-hydroxytryptamine methyltransferase;

[0103] 2. Using the above codon-optimized target gene sequence as a template, PCR amplification was performed to obtain DNA fragments of NfTPH, CKvTDC, SgSNAT, and HsASMT;

[0104] (II) Construction of recombinant expression plasmid

[0105] In this example, except that the "gene AlTPH encoding tryptophan hydroxylase" in Example 1 is replaced by "gene NfTPH encoding tryptophan hydroxylase", the rest of the method for constructing the recombinant expression plasmid can be carried out with reference to Example 1 to obtain the pUrlp-NfTPH-CKvTDC-SgSNAT-HsASMT Yarrowia lipolytica chromosome site-directed recombination plasmid.

[0106] Comparative Example 1

[0107] (I) Synthesis and amplification of target genes:

[0108] 1. Obtain the codon-optimized gene CKvTDC encoding tryptophan decarboxylase using gene synthesis technology;

[0109] The codon-optimized gene SgSNAT encoding serotonin n-acetyltransferase;

[0110] The codon-optimized gene HsASMT encoding n-acetyl 5-hydroxytryptamine methyltransferase;

[0111] 2. Using the above codon-optimized target gene sequence as a template, PCR amplification was performed to obtain DNA fragments of CKvTDC, SgSNAT, and HsASMT;

[0112] (II) Construction of recombinant expression plasmid

[0113] In the construction process of the recombinant expression plasmid of this embodiment, except that the "gene AlTPH encoding tryptophan hydroxylase" is not included, the rest of the method for constructing the recombinant expression plasmid can be carried out with reference to Example 1 to obtain the pUrlp-CKvTDC-SgSNAT-HsASMT Yarrowia lipolytica chromosome site-directed recombination plasmid.

[0114] Example 3

[0115] (i) Preparation of competent cells of Yarrowia lipolytica chassis strain.

[0116] The Yarrowia lipolytica chassis strains are Po1g (leucine Leu deficiency type) and Po1fk (leucine Leu and uracil Ura double deficiency type).

[0117] The bottom plate strain was inoculated into a test tube containing 3 mL of YPD (Yeast extract Peptone Dextrose; 1% yeast extract, 2% glucose and 20% peptone) medium and cultured overnight in a shaking incubator at 30°C and 250 rpm;

[0118] Take 1 mL of the bottom plate yeast solution and centrifuge at low speed, discard the supernatant, and mix the cell pellet thoroughly with 95 μL 50% PEG4000 and 5 μL 2M lithium acetate solution;

[0119] The chassis competent cells of the Yarrowia lipolytica engineering strain for preparing high-yield melatonin are obtained.

[0120] (ii) Engineered strains capable of biosynthesizing melatonin using L-tryptophan as a substrate

[0121] 1. Integration of target gene into Yarrowia lipolytica pBR platform

[0122] The recombinant expression vector pYLXP'-AlTPH-CKvTDC-SgSNAT-HsASMT obtained in Example 1 was linearized by single restriction enzyme NotI (endonuclease 6) to obtain a linear DNA carrying four target genes of AlTPH, CKvTDC, SgSNAT, HsASMT and the LEU2 selection marker gene;

[0123] 2. Thoroughly mix 10 μL of the above linear DNA and 5 μL of boiled ssDNA (deformed fish sperm DNA), and add to the competent cells of the Po1g chassis strain obtained in (a);

[0124] Place in a 39°C water bath for 1 hour, vortexing for 15 seconds every 10 minutes;

[0125] 3. Apply to SD-Leu (20 g / L glucose, 1.7 g / L yeast nitrogen matrix without ammonium sulfate, 5 g / L ammonium sulfate ((NH4)SO4), 1.29 g / L defective amino acid lacking leucine Leu) plate for screening;

[0126] Four target genes were integrated into the pBR platform of Yarrowia lipolytica to obtain an engineered strain capable of biosynthesizing melatonin using L-tryptophan as a substrate.

[0127] (III) Preparation of an engineered strain of Yarrowia lipolytica that produces high levels of melatonin

[0128] 1. Integrate the target gene into the Ku70 locus of Yarrowia lipolytica chromosome

[0129] The recombinant expression vector pUrlp-CKvTDC-SgSNAT-HsASMT obtained in Example 1 was linearized by single enzyme digestion with AvrII (endonuclease 5) to obtain a linear DNA containing the homologous sequence of the Ku70 gene, three target genes CKvTDC, SgSNAT, and HsASMT, and the URA3 selection marker gene;

[0130] 10 μL of the above linear DNA and 5 μL of boiled ssDNA (deformed fish sperm DNA) were thoroughly mixed and added to the competent cells of the Po1fk chassis strain obtained in (a);

[0131] Place in a 39°C water bath for 1 hour, vortexing for 15 seconds every 10 minutes;

[0132] The cells were plated on SD-Ura (20 g / L glucose, 1.7 g / L yeast nitrogen matrix without ammonium sulfate, 5 g / L ammonium sulfate ((NH4)SO4), 1.29 g / L uracil-deficient Ura-deficient amino acids) plates for screening.

[0133] An engineered strain was obtained in which the three target genes CKvTDC, SgSNAT, HsASMT and the URA3 selection marker gene were integrated into the Ku70 gene site of the Yarrowia lipolytica chromosome;

[0134] Achieve efficient biosynthesis of melatonin using 5-hydroxytryptamine as substrate.

[0135] 2. Cre-LoxP technology to recover URA3 selection marker gene

[0136] The pYLXP'-Cre plasmid is transformed into the engineered strain obtained in step 1 above; by expressing the Cre enzyme, the URA3 selection marker gene is cut off and recovered, thereby obtaining an engineered strain that is deficient in uracil Ura and has the ability to efficiently synthesize melatonin using 5-hydroxytryptamine as a substrate, so as to reuse the pUrlp vector plasmid for gene integration at different chromosome sites.

[0137] 3. Integration of target gene into ARO8 locus of Yarrowia lipolytica chromosome

[0138] The recombinant expression vector pUrlp-AlTPH obtained in Example 1 was linearized by single enzyme digestion with AvrII (endonuclease 5) to obtain a linear DNA carrying the homologous sequence of the ARO8 gene, the AlTPH target gene and the URA3 selection marker gene;

[0139] The linear DNA is transformed into the uracil Ura-deficient engineered strain obtained in step 2, which has the ability to efficiently synthesize melatonin using 5-hydroxytryptamine as a substrate, and the AlTPH target gene is integrated into the ARO8 gene locus and the ARO8 gene is knocked out simultaneously by the same method as in step 1;

[0140] An engineered strain was obtained in which the four target genes AlTPH, CKvTDC, SgSNAT and HsASMT were all integrated into the chromosome; and efficient biosynthesis of melatonin using L-tryptophan as a substrate was achieved.

[0141] Example 4

[0142] In this example, the "recombinant expression vector pYLXP'-AlTPH-CKvTDC-Sg SNAT-HsASMT obtained in Example 1" used in Example 3 was replaced by:

[0143] Except for “the recombinant expression vector pUrlp-NfTPH-CKvTDC-SgSNAT-HsASMT obtained in Example 2”, the rest is the same as Example 3.

[0144] An engineered strain was obtained in which the four target genes NfTPH, CKvTDC, SgSNAT and HsASMT were all integrated into the chromosome; and efficient biosynthesis of melatonin using L-tryptophan as a substrate was achieved.

[0145] Comparative Example 2

[0146] In this comparative example, the "recombinant expression vector pYLXP'-AlTPH-CKvTDC-SgSNAT-HsASMT obtained in Example 1" used in Example 3 was replaced by:

[0147] Except for the “recombinant expression vector pUrlp-CKvTDC-SgSNAT-HsASMT obtained in Comparative Example 1”, the rest is the same as Example 3.

[0148] An engineered strain was obtained in which the three target genes CKvTDC, SgSNAT and HsASMT were all integrated into the chromosome.

[0149] Experimental Example 1: Fermentation of engineered strains and detection of melatonin content

[0150] (I) Fermentation of an engineered strain of Yarrowia lipolytica that produces high levels of melatonin

[0151] The Yarrowia lipolytica engineered strains containing the complete melatonin synthesis pathway starting from L-tryptophan prepared in Examples 3, 4 and Comparative Example 1 were inoculated into test tubes containing 3 mL YPD medium and cultured overnight in a shaking incubator at 30° C. and 250 rpm;

[0152] About 1 mL of bacterial liquid was added to a 250 mL baffled flask containing 25 mL of YPD medium supplemented with 1 g / L tryptophan, and the flask was placed in a shaker at 30°C and 250 rpm for shake fermentation for 5 days.

[0153] (II) Extraction and content detection of melatonin

[0154] 1. Take 1 mL of fermentation broth, centrifuge it, take the supernatant, add methanol to dilute it 5 times, and get the final test sample.

[0155] 2. Use high performance liquid chromatography and liquid chromatography-mass spectrometry to detect and quantify melatonin.

[0156] The chromatography was performed using an Agilent 1260infinity liquid chromatograph and a reversed-phase C18 column (ZORBAX Eclipse Plus C18 (3.5 μm, 4.6 mm × 100 mm) with UV detection at 286 nm;

[0157] The mobile phase of the high performance liquid chromatography is solvent A (water containing 1% formic acid) and solvent B (methanol), the flow rate is 0.5 min / mL, and the temperature is 30°C; the elution gradient conditions are: 0-5 min, 30-40% B; 5-10 min, 40-45% B; 10-16 min, 45% B; 16-17 min, 45-100% B; 17-22 min, 100% B; 22-23 min, 100-30% B.

[0158] Using Thermo Scientific TM Orbitrap Exploris TM 120 mass spectrometer for LC-MS (liquid chromatography-mass spectrometry) analysis of melatonin;

[0159] Using Thermo Scientific TM Chromatographic separation was performed on an AccucoreTM aQ C18 polar capped LC column (2.6 μm, 150 mm×2.1 mm); the mobile phase consisted of A (water containing 0.1% v / v formic acid) and B (methanol). The flow rate was set at 0.5 ml min-1. The gradient elution was as follows: 30-40% B at 0-5 min, 40-45% B at 5-10 min, 45% B at 10-16 min, 45-100% B at 16-17 min, 100% B at 17-22 min, and 100-30% B at 22-23 min;

[0160] MS detection and scanning parameters were configured as H-ESI ion source type, spray voltage 3500 V, temperature 350 °C, and Orbitrap resolution 15000; unknown compounds were obtained by Thermo Scientific TM Compound Discoverer TM Software-assisted identification.

[0161] The final melatonin production is shown in the following table:

[0162] Group Melatonin production Example 3 Engineering strains 230.60±7.87mg / L Example 4 Engineering strains 208.23±5.56mg / L Comparative Example 2 Engineering strains 54.56±1.97mg / L

[0163] As can be seen from the above table, Examples 3 and 4 have a significant high-yield advantage in melatonin production compared to the strain in Comparative Example 2, which indicates that the codon-optimized tryptophan hydroxylase encoding gene AlTPH and the codon-optimized tryptophan hydroxylase encoding gene NfTPH in the present application can effectively improve the catalytic activity of hydroxylating L-tryptophan to 5-hydroxytryptophan, increase 5-HTP, and thus increase the melatonin production in the Yarrowia lipolytica engineered strain; it also proves that the Yarrowia lipolytica engineered strain prepared in the present application has the ability to produce high melatonin using L-tryptophan as a substrate.

[0164] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An engineered strain of Yarrowia lipolytica, characterized in that The genome of the Yarrowia lipolytica engineered strain comprises: The codon-optimized gene encoding tryptophan hydroxylase, AlTPH; and, the codon-optimized gene encoding tryptophan decarboxylase, CKvTDC; and, the codon-optimized gene encoding serotonin n -acetyltransferase, SgSNAT; and, the codon-optimized gene encoding n-acetyl 5-hydroxytryptamine methyltransferase HsASMT.

2. The Yarrowia lipolytica engineered strain according to claim 1, characterized in that The codon-optimized nucleotide sequence encoding the tryptophan hydroxylase gene AlTPH is shown in SEQ ID NO.1; And / or, the codon-optimized nucleotide sequence encoding the tryptophan decarboxylase gene CKvTDC is shown in SEQ ID NO.2; and / or, the nucleotide sequence of the codon-optimized 5-hydroxytryptamine n-acetyltransferase gene SgSNAT is shown in SEQ ID NO.3; And / or, the nucleotide sequence encoding the n-acetyl 5-hydroxytryptamine methyltransferase gene HsASMT after codon optimization is shown in SEQ ID NO.

4.

3. The Yarrowia lipolytica engineered strain according to claim 1, characterized in that The codon-optimized tryptophan hydroxylase encoding gene AlTPH can be replaced by: The codon-optimized gene encoding tryptophan hydroxylase NfTPH.

4. The engineered strain of Yarrowia lipolytica according to claim 3, characterized in that The codon-optimized nucleotide sequence encoding the tryptophan hydroxylase gene NfTPH is shown in SEQ ID NO.

5.

5. The engineered strain of Yarrowia lipolytica according to claim 1, characterized in that The Yarrowia lipolytica engineered strain is a Yarrowia lipolytica strain in which the endogenous genes ARO8 and MET25 are knocked out.

6. Use of the engineered strain of Yarrowia lipolytica according to any one of claims 1 to 5 in preparing a strain capable of biosynthesizing melatonin.

7. Application of the codon-optimized tryptophan hydroxylase encoding gene AlTPH and the codon-optimized tryptophan hydroxylase encoding gene NfTPH in constructing a Yarrowia lipolytica strain with higher L-tryptophan hydroxylation catalytic activity; The L-tryptophan hydroxylation catalysis is to hydroxylate L-tryptophan into 5-hydroxytryptophan.

8. A method for constructing an engineered strain of Yarrowia lipolytica having the function of biosynthesizing melatonin, characterized in that: The method comprises: (A) Gene synthesis technology was used to obtain the codon-optimized tryptophan hydroxylase encoding gene AlTPH; and, the codon-optimized gene encoding tryptophan decarboxylase, CKvTDC; and, the codon-optimized gene encoding serotonin n -acetyltransferase, SgSNAT; and, the codon-optimized gene encoding n -acetyl 5-hydroxytryptamine methyltransferase, HsASMT; (B) Using the codon-optimized gene sequence encoding the tryptophan hydroxylase gene AlTPH as a template, the AlTPH gene expression cassette was cloned; Using the codon-optimized gene sequence encoding the tryptophan decarboxylase gene CKvTDC as a template, the CKvTDC gene expression cassette was cloned; Using the codon-optimized gene sequence encoding 5-hydroxytryptamine n-acetyltransferase gene SgSNAT as a template, the SgSNAT gene expression cassette was cloned; Using the codon-optimized gene sequence encoding the n-acetyl 5-hydroxytryptamine methyltransferase gene HsASMT as a template, the HsASMT gene expression cassette was cloned; (C) connecting the AlTPH gene expression cassette, CKvTDC gene expression cassette, SgSNAT gene expression cassette, and HsASMT gene expression cassette obtained in step (B) into the linear vector respectively; An expression vector containing the AlTPH gene, an expression vector containing the CKvTDC gene, an expression vector containing the SgSNAT gene, and an expression vector containing the HsASMT gene were constructed respectively; (D) The expression vector containing the AlTPH gene, the expression vector containing the CKvTDC gene, the expression vector containing the SgSNAT gene, and the expression vector containing the HsASMT gene obtained in step (C) are transferred into the Yarrowia lipolytica strain, and the endogenous gene ARO8 is knocked out. After screening, an engineered Yarrowia lipolytica strain with the function of biosynthesizing melatonin is obtained.

9. The method for constructing an engineered strain of Yarrowia lipolytica having the function of biosynthesizing melatonin according to claim 8, characterized in that: The step (D) is to transfer the gene by mediating lithium acetate-PEG.

10. The method for constructing an engineered strain of Yarrowia lipolytica having the function of biosynthesizing melatonin according to claim 8, characterized in that: The screening in step (D) uses the URA3 gene as a screening marker to achieve screening of yeast colonies containing the target introduced gene cassette.